The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp reported its full year 2025 financial results alongside key corporate developments.
The company disclosed these updates through an official press release, signaling an intent to maintain transparency on performance and strategy. Investors and industry observers can access the full details by consulting the published release. Details are being clarified.
As Camp4 Therapeutics navigates the forthcoming year, its recent financial disclosures build upon ongoing engagement with the SYNGAP1 community, as demonstrated during the family day event in Poland. These strategic developments also align with the company’s sustained efforts to advance its ASO platform targeting gene expression in SYNGAP1 treatment, signaling a broader commitment to both transparency and innovation in the biotech sector.